Brian Hosung Min

Brian Hosung Min currently serves as the Executive Vice President at Samsung Biologics since August 2023. Prior to this role, Brian was the CEO of GenScript ProBio from March 2019 to August 2023 and held multiple senior positions at Samsung Bioepis, including Senior Vice President and Vice President of Process Team from April 2012 to August 2023, overseeing process development and manufacturing for all biosimilar products. Brian's earlier experience includes a Vice President role at Samsung Electronics focused on biosimilar process development and business development, and as Head of Antibody Engineering at Samsung, where novel antibody-based therapeutic platforms were developed. Brian's career began at Amgen as a Principal Scientist, where significant contributions to phage-display based protein therapeutics and antibody development were made. Educational background includes a Ph.D. in Molecular Biology from UCLA and a BA in Molecular Biology from the University of California, Berkeley.